The Correlation Between Novel Survival-related Alternative Splicing Signature and Prognostic Prediction and Immune Microenvironment in Clear Cell Renal Cell Carcinoma

BackgroundAlthough extensive researches related alternative splicing (AS) as the prognostic markers of patients in cancers, which remains unknown in clear cell renal cell carcinoma (ccRCC), especially in immunotherapy. Therefore, a novel survival-associated AS signature was established to predict prognosis of patients and explored its correlation with immune cell infiltration or immune checkpoint expression to explain the phenomenon of resistance to immunotherapy in ccRCC.Methodsccording to AS data, clinical information and gene expression data in ccRCC, overall survival-related AS events was identified and further the AS-related prognostic risk model established by LASSO regression and multi-Cox regression analysis was evaluated by Kaplan-Meier survival analysis, the ROC curves and a nomogram model. Then we clarified the biological processes and pathways by GSEA, and further measured the immune cell infiltration by ESTIMATE, CIBERSORT and ssGSEA. Finally we analysed the clinical features and immune features of different parental genes, and quested the splicing factors regulating riskScore-related AS events by Spearman correlation analysis.ResultsWe obtained the most significant 5 AS events, including C4orf19|69001|AT, UACA|31438|AP, FAM120C|89237|AT, TRIM16L|39629|AP and SEC31A|100881|ES, to establish the prognostic risk model, and further illustrated the stability and importance of the riskScore prognostic signatures. Then we found that in high risk group, most of the top 10 GO enrichments and the KEGG pathway were closely related to the immunity, and the higher immune cell infiltration, and higher expression of classic immune checkpoints such as PD1 and CTLA4. In addition, 6 different parental genes were obtained, including C4orf19, ARHGAP24 DNASE1L3, P4HA1, SLC39A14 and TAF1D. These 6 genes could not be the independent prognostic signatures, but the expression of these genes was closely related to immune cells infiltration and the expression of immune checkpoints. Finally, we got aberrant 52 splicing factors regulating riskScore-related AS events.ConclusionOur study discovered that overall survival-related AS events mediated by aberrant splicing factors can be constructed a prognostic risk model to predict prognosis of patiens and utilized to index the situation of immune cell infiltration and immune checkpoint expression that impact tumor immune microenvironment in ccRCC.

[1]  Gong Yang,et al.  Extracellular matrix protein-1 secretory isoform promotes ovarian cancer through increasing alternative mRNA splicing and stemness , 2021, Nature Communications.

[2]  Yuan Zhang,et al.  The landscape and biological relevance of aberrant alternative splicing events in esophageal squamous cell carcinoma , 2021, Oncogene.

[3]  Xiaobing Jiang,et al.  Identification and Validation of a Prognostic Immune-Related Alternative Splicing Events Signature for Glioma , 2021, Frontiers in Oncology.

[4]  Chuan Liu,et al.  Identification of Tumor Microenvironment-Related Alternative Splicing Events to Predict the Prognosis of Endometrial Cancer , 2021, Frontiers in Oncology.

[5]  B. Yu,et al.  Alternative Splicing Events in Tumor Immune Infiltration in Colorectal Cancer , 2021, Frontiers in Oncology.

[6]  Mugen Liu,et al.  Comprehensive characterization of alternative splicing in renal cell carcinoma , 2021, Briefings Bioinform..

[7]  M. Stern,et al.  Splicing patterns in SF3B1 mutated uveal melanoma generate shared immunogenic tumor-specific neo-epitopes. , 2021, Cancer Discovery.

[8]  Hao Xu,et al.  Immunological significance of prognostic alternative splicing signature in hepatocellular carcinoma , 2021, Cancer cell international.

[9]  Steven L. Chang,et al.  Tumor and immune reprogramming during immunotherapy in advanced renal cell carcinoma , 2021, Cancer cell.

[10]  Steven L. Chang,et al.  Progressive immune dysfunction with advancing disease stage in renal cell carcinoma. , 2021, Cancer cell.

[11]  R. Rabadán,et al.  Computing the Role of Alternative Splicing in Cancer. , 2021, Trends in cancer.

[12]  E. V. Van Allen,et al.  Beyond conventional immune-checkpoint inhibition — novel immunotherapies for renal cell carcinoma , 2021, Nature Reviews Clinical Oncology.

[13]  Yingwei Xue,et al.  The landscape of alternative splicing reveals novel events associated with tumorigenesis and the immune microenvironment in gastric cancer. , 2021, Aging.

[14]  W. Rathmell,et al.  Clear cell renal cell carcinoma ontogeny and mechanisms of lethality , 2020, Nature Reviews Nephrology.

[15]  E. Giovannetti,et al.  The role of alternative splicing in cancer: From oncogenesis to drug resistance. , 2020, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[16]  Lin Zhu,et al.  Identification of Novel Alternative Splicing Events Associated With Tumorigenesis, Protein Modification, and Immune Microenvironment in Early-Onset Gastric Cancer , 2020, bioRxiv.

[17]  Fan Lin,et al.  Comprehensive analysis and establishment of a prediction model of alternative splicing events reveal the prognostic predictor and immune microenvironment signatures in triple negative breast cancer , 2020, Journal of Translational Medicine.

[18]  Z. Ye,et al.  HnRNP A1 - mediated alternative splicing of CCDC50 contributes to cancer progression of clear cell renal cell carcinoma via ZNF395 , 2020, Journal of Experimental & Clinical Cancer Research.

[19]  G. Narla,et al.  Splice of Life for Cancer: Missplicing of PPP2R5A by Mutant SF3B1 Leads to MYC Stabilization and Tumorigenesis. , 2020, Cancer discovery.

[20]  J. Valcárcel,et al.  Roles and mechanisms of alternative splicing in cancer — implications for care , 2020, Nature Reviews Clinical Oncology.

[21]  L. Pasqualucci,et al.  Mutations in the RNA splicing factor SF3B1 promote tumorigenesis through MYC stabilization. , 2020, Cancer discovery.

[22]  A. Jemal,et al.  Cancer statistics, 2020 , 2020, CA: a cancer journal for clinicians.

[23]  Xianxin Li,et al.  Systematic analysis of survival‐associated alternative splicing signatures in clear cell renal cell carcinoma , 2019, Journal of cellular biochemistry.

[24]  Jing Huang,et al.  Survival-Associated Alternative Splicing Events in Pan-Renal Cell Carcinoma , 2019, Front. Oncol..

[25]  J. Nielsen,et al.  Classification of clear cell renal cell carcinoma based on PKM alternative splicing , 2019, bioRxiv.

[26]  Jun Ma,et al.  Comprehensive characterization of the alternative splicing landscape in head and neck squamous cell carcinoma reveals novel events associated with tumorigenesis and the immune microenvironment , 2019, Theranostics.

[27]  D. Baltimore,et al.  Alternative mRNA splicing in cancer immunotherapy , 2019, Nature Reviews Immunology.

[28]  F. Liu,et al.  HnRNPL promotes Wilms tumor progression by regulating the p53 and Bcl2 pathways , 2019, OncoTargets and therapy.

[29]  Jiaming Su,et al.  Systematic analysis of alternative splicing signature unveils prognostic predictor for kidney renal clear cell carcinoma , 2019, Journal of cellular physiology.

[30]  H. Kume,et al.  Discovery of Functional Alternatively Spliced PKM Transcripts in Human Cancers , 2019, bioRxiv.

[31]  Angela N. Brooks,et al.  A Murine Model of Chronic Lymphocytic Leukemia Based on B Cell-Restricted Expression of Sf3b1 Mutation and Atm Deletion. , 2019, Cancer cell.

[32]  R. May,et al.  Alternative splice variants of DCLK1 mark cancer stem cells, promote self‐renewal and drug‐resistance, and can be targeted to inhibit tumorigenesis in kidney cancer , 2018, International journal of cancer.

[33]  Jun Luo,et al.  Alternative splicing in prostate cancer , 2018, Nature Reviews Clinical Oncology.

[34]  Steven J. M. Jones,et al.  Comprehensive Analysis of Alternative Splicing Across Tumors from 8,705 Patients , 2018, Cancer cell.

[35]  L. Zender,et al.  PTBP1-Mediated Alternative Splicing Regulates the Inflammatory Secretome and the Pro-tumorigenic Effects of Senescent Cells , 2018, Cancer cell.

[36]  Zoltan Szallasi,et al.  Deterministic Evolutionary Trajectories Influence Primary Tumor Growth: TRACERx Renal , 2018, Cell.

[37]  Ping Zhu,et al.  Somatic Mutational Landscape of Splicing Factor Genes and Their Functional Consequences across 33 Cancer Types. , 2018, Cell reports.

[38]  B. Rini,et al.  Treatment of renal cell carcinoma: Current status and future directions , 2017, CA: a cancer journal for clinicians.

[39]  F. Baralle,et al.  Alternative splicing as a regulator of development and tissue identity , 2017, Nature Reviews Molecular Cell Biology.

[40]  C. Duan,et al.  Polypyrimidine Tract-Binding Protein 1 promotes proliferation, migration and invasion in clear-cell renal cell carcinoma by regulating alternative splicing of PKM. , 2017, American journal of cancer research.

[41]  Qihong Huang,et al.  Alternative Splicing of EZH2 pre-mRNA by SF3B3 Contributes to the Tumorigenic Potential of Renal Cancer , 2016, Clinical Cancer Research.

[42]  P. A. van den Brandt,et al.  A Four-Gene Promoter Methylation Marker Panel Consisting of GREM1, NEURL, LAD1, and NEFH Predicts Survival of Clear Cell Renal Cell Cancer Patients , 2016, Clinical Cancer Research.

[43]  Gianluca Bontempi,et al.  TCGAbiolinks: an R/Bioconductor package for integrative analysis of TCGA data , 2015, Nucleic acids research.

[44]  Robert Brown,et al.  TCGASpliceSeq a compendium of alternative mRNA splicing in cancer , 2015, Nucleic Acids Res..

[45]  David Allman,et al.  Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 Immunotherapy. , 2015, Cancer discovery.

[46]  IRF-1 regulates alternative mRNA splicing of carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1) in breast epithelial cells generating an immunoreceptor tyrosine-based inhibition motif (ITIM) containing isoform , 2014, Molecular Cancer.

[47]  Jian Zhang,et al.  Misregulation of pre-mRNA alternative splicing in cancer. , 2013, Cancer discovery.

[48]  Z. Szallasi,et al.  Prognostic and predictive markers in metastatic renal cell carcinoma. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[49]  Han Yong Choi,et al.  The epidemiology of renal cell carcinoma. , 2011, European urology.